Mounjaro vs Ozempic: New Weight-Loss Drug Arrives in India

The fight against obesity and diabetes in India just got a new contender. US pharmaceutical giant Eli Lilly has launched Mounjaro, its highly anticipated diabetes and weight-loss medication, in the Indian market. Priced at Rs 3,500 for a 2.5 mg vial, Mounjaro’s arrival is generating considerable buzz, especially given the existing popularity of similar medications like Ozempic.

Is Mounjaro Better Than Ozempic?

Many are wondering if Mounjaro offers advantages over Ozempic. While both drugs address diabetes and aid in weight loss, they utilize different mechanisms. Mounjaro (Tirzepatide) activates both GIP and GLP-1 receptors, potentially leading to greater efficacy in some individuals. Ozempic (Semaglutide) only activates the GLP-1 receptor. More research is needed to definitively compare their long-term effects and suitability for different patients.

Mounjaro’s Price and Availability in India

With a price tag of Rs 3,500 for a 2.5 mg vial, Mounjaro’s cost is a significant factor for Indian consumers. Its availability will be crucial in determining its impact on the market. As more people gain access to the medication, real-world data will emerge, providing a clearer picture of its effectiveness and potential side effects in the Indian population.